Sunitinib Malate Capsule
Product Images NDC 42291-902

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sunitinib Malate (NDC 42291-902). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

12.5 (901 28)

12.5 (901 28)
FDA Label Image

25 (902 28)

25 (902 28)
FDA Label Image

37.5 (903 28)

37.5 (903 28)
FDA Label Image

50 (904 28)

50 (904 28)
FDA Label Image

1 (Image 1)

1 (Image 1)
FDA Label Image

1 (Image 2)

1 (Image 2)
This is a description of a study evaluating the time to tumor progression in patients treated with Sunitinib Malate compared to a placebo. The study included a total of 207 patients in the Sunitinib Malate group and 105 patients in the placebo group. The median time to tumor progression in the Sunitinib Malate group was 27.3 weeks, while in the placebo group it was 6.4 weeks. The hazard ratio, which measures the risk of tumor progression, was 0.33, indicating a lower risk in the Sunitinib Malate group. This result is statistically significant with a p-value of less than 0.0001.*
FDA Label Image

1 (Image 3)

1 (Image 3)
The available text provides information about a comparison between Sunitinib Malate and IFN-a for a group of 375 individuals. The median survival time for Sunitinib Malate is 47.3 weeks, while for IFN-a it is 22.0 weeks. The hazard ratio between the two treatments is 0.42 (indicating a lower risk of progression with Sunitinib Malate), with a 95% confidence interval of 0.32 to 0.54. The progression-free survival probability is 8%. The data also includes a graph showing the number of subjects at risk over time. Unfortunately, the could not accurately read the remaining text.*
FDA Label Image

1 (Image 4)

1 (Image 4)
FDA Label Image

1 (Image 5)

1 (Image 5)
Not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.